Moderna said on Monday its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Influenza hemagglutinin subunit vaccines are more effective and offer better cross protection against various influenza virus ...

Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.

FluMist is the first vaccine to prevent influenza, more commonly known as the flu, that does not need to be administered by a ...

The CDC panel voted against an ingredient that the anti-vaccine movement has long targeted, while Arcadia was acquired by ...

A CDC advisory has recommended to ban the use of thimerosal in flu shots despite no evidence that it causes any harm.

A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

CDC advisory committee recommends thimerosal-free influenza vaccines for all adults and children, despite claims that the ...